Can endometriosis be mistaken for fatty liver disease? Whilst these conditions affect different organ systems—endometriosis involving reproductive tissues and fatty liver affecting the liver—diagnostic confusion can occasionally arise when symptoms overlap or rare manifestations occur. Endometriosis affects approximately 1.5 million women in the UK, causing pelvic pain and fertility problems, whilst non-alcoholic fatty liver disease (NAFLD) affects up to 25% of the population, often silently. Both can cause abdominal discomfort and fatigue, and in exceptionally rare cases, endometriotic tissue can implant on the liver itself. Understanding the distinctions between these conditions ensures accurate diagnosis and appropriate specialist referral.

Understanding Endometriosis and Fatty Liver Disease

Endometriosis and fatty liver disease are two distinct medical conditions affecting different organ systems, yet both can present with overlapping symptoms that occasionally lead to diagnostic uncertainty. Understanding the fundamental differences between these conditions is essential for accurate diagnosis and appropriate management.

Endometriosis is a chronic gynaecological condition affecting approximately 1.5 million women in the UK. It occurs when tissue similar to the endometrium (the lining of the womb) grows outside the uterus, commonly on the ovaries, fallopian tubes, and pelvic peritoneum. In a subset of women with deep infiltrating disease, endometriotic lesions can involve the bowel. Exceptionally rare sites include the liver and diaphragm, documented mainly in case reports. The condition is oestrogen-dependent and typically affects women of reproductive age, causing pelvic pain, dysmenorrhoea (painful periods), and fertility problems.

Fatty liver disease, medically termed hepatic steatosis, involves the accumulation of excess fat within liver cells. The two main types are non-alcoholic fatty liver disease (NAFLD), which affects up to 25% of the UK population, and alcohol-related fatty liver disease. NAFLD is strongly associated with metabolic syndrome, obesity, type 2 diabetes, and dyslipidaemia. The spectrum ranges from simple steatosis through non-alcoholic steatohepatitis (NASH, with inflammation and liver cell damage) to fibrosis and cirrhosis. Most individuals with NAFLD remain asymptomatic, though some may experience vague right upper quadrant discomfort or fatigue.

Whilst endometriosis primarily affects the reproductive organs and fatty liver disease is a hepatic condition, both can occasionally cause abdominal pain and systemic symptoms. Non-specific symptom presentation means that clinicians must maintain a broad differential diagnosis when evaluating patients with abdominal complaints. Accurate diagnosis requires careful clinical assessment, appropriate imaging, and sometimes invasive investigations. (NICE NG73: Endometriosis; NICE NG49: Non-alcoholic fatty liver disease)

Can Endometriosis Be Mistaken for Fatty Liver?

Direct misdiagnosis between endometriosis and fatty liver disease appears uncommon in clinical practice due to their distinct presentations and diagnostic pathways. However, there are specific scenarios where confusion may arise, particularly when symptoms overlap or when rare manifestations of endometriosis occur.

There is no evidence suggesting that standard pelvic endometriosis is routinely mistaken for fatty liver disease. The conditions affect different organ systems and are typically investigated through separate pathways—gynaecological assessment for endometriosis and hepatological or metabolic evaluation for fatty liver. However, diagnostic uncertainty can emerge when patients present with non-specific abdominal pain, as both conditions may contribute to abdominal discomfort in certain circumstances.

An exceptionally rare but documented phenomenon is hepatic endometriosis, where endometriotic tissue implants on or within the liver. This is reported mainly in case reports and case series, and true prevalence is unknown. When present, it can cause right upper quadrant pain, particularly in a cyclical pattern corresponding to menstruation. Imaging studies may reveal liver lesions that could initially be misinterpreted as other hepatic pathology, including cysts or tumours. Conversely, abdominal ultrasound performed for non-specific abdominal pain might detect hepatic steatosis; pelvic ultrasound targets pelvic organs and will not assess the liver.

The potential for confusion is further complicated when patients have coexisting conditions. Women with endometriosis may independently develop fatty liver disease, particularly if they have metabolic risk factors such as polycystic ovary syndrome (PCOS), obesity, or insulin resistance. In such cases, clinicians must carefully evaluate which condition is responsible for specific symptoms and ensure both are appropriately managed. Thorough history-taking, including menstrual patterns, pain characteristics, and metabolic risk factors, helps distinguish between these conditions and identify when both may be present simultaneously. (NICE NG73; BMJ Case Reports and World Journal of Gastroenterology reviews on hepatic endometriosis)

Why These Conditions May Be Confused: Symptoms and Diagnosis

Several factors contribute to potential diagnostic overlap between endometriosis and fatty liver disease, primarily relating to symptom presentation and the non-specific nature of abdominal pain.

Symptom overlap is the most common source of confusion. Both conditions can cause:

• Abdominal pain or discomfort: Endometriosis typically causes pelvic pain, but extensive disease or exceptionally rare sites (such as diaphragmatic or hepatic endometriosis) can produce upper abdominal symptoms. Fatty liver disease is usually asymptomatic; when symptoms occur, they may include vague right upper quadrant discomfort or a sensation of fullness.

• Fatigue: Both conditions are associated with significant tiredness, though through different mechanisms—chronic inflammation and pain in endometriosis versus metabolic dysfunction in fatty liver disease.

Diagnostic challenges arise when initial investigations are non-specific. Transvaginal or pelvic ultrasound is used to evaluate suspected endometriosis (identifying endometriomas and deep infiltrating disease), whilst abdominal ultrasound assesses hepatic steatosis. If the clinical presentation is unclear, appropriate imaging of both pelvic and upper abdominal organs may be required.

Atypical presentations further complicate diagnosis. Diaphragmatic endometriosis, though exceptionally rare, can cause right shoulder pain (referred pain via the phrenic nerve) and upper abdominal symptoms that might prompt hepatic investigation. In fatty liver disease, symptoms alone cannot distinguish simple steatosis from NASH; blood tests and non-invasive fibrosis assessment are required.

Clinicians must maintain awareness that multiple pathologies can coexist. The presence of one condition does not exclude another, and thorough evaluation of all presenting symptoms is essential to avoid anchoring bias and ensure comprehensive diagnosis. (NICE NG49; NHS Non-alcoholic fatty liver disease page)

Diagnostic Tests to Distinguish Between the Two Conditions

Accurate differentiation between endometriosis and fatty liver disease requires a systematic diagnostic approach utilising clinical assessment, laboratory investigations, and imaging modalities appropriate to each condition.

Clinical history and examination form the foundation of diagnosis. For endometriosis, key features include cyclical pelvic pain, dysmenorrhoea, dyspareunia (painful intercourse), and subfertility. Physical examination may reveal pelvic tenderness, fixed retroverted uterus, or palpable nodules. For fatty liver disease, clinicians assess metabolic risk factors including body mass index (BMI), waist circumference, alcohol consumption, and features of metabolic syndrome.

Laboratory investigations provide distinct diagnostic information:

• For endometriosis: There is no definitive blood test. CA-125 may be mildly elevated in moderate to severe disease but lacks specificity and is not routinely recommended by NICE for diagnosis.

• For fatty liver disease: Liver function tests (LFTs) may show mildly elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST), though these can be normal in simple steatosis. Additional tests include fasting glucose, HbA1c, lipid profile, and exclusion of other liver pathology (hepatitis serology, ferritin, autoimmune markers).

Imaging modalities are crucial for distinguishing these conditions:

• Pelvic ultrasound (transvaginal) is first-line for suspected endometriosis, identifying endometriomas and deep infiltrating disease when performed by experienced practitioners. However, superficial peritoneal disease may be missed, and NICE guidance allows empirical management based on clinical suspicion without laparoscopy in some cases.

• Abdominal ultrasound readily detects hepatic steatosis, appearing as increased echogenicity of the liver parenchyma. This is typically the initial investigation for suspected fatty liver.

• MRI provides superior soft tissue characterisation and is valuable for mapping deep endometriosis, including exceptionally rare hepatic or diaphragmatic lesions. MRI can also quantify hepatic fat content; specialised MR elastography (not routine in UK pathways) can assess fibrosis.

Non-invasive fibrosis assessment for NAFLD includes:

• Enhanced Liver Fibrosis (ELF) test: NICE-recommended blood test for detecting advanced fibrosis (NICE DG34).

• FIB-4 and NAFLD fibrosis score: Widely used in UK primary care pathways (supported by British Society of Gastroenterology guidance) for risk stratification.

• Transient elastography (FibroScan): Commonly used to assess liver stiffness and fat content; elevated results prompt hepatology referral.

Definitive diagnosis of endometriosis may require laparoscopy with histological confirmation, considered the gold standard, though NICE supports empirical treatment in many cases. For fatty liver disease, liver biopsy is reserved for cases where NASH or significant fibrosis is suspected and non-invasive tests are inconclusive. The distinct diagnostic pathways for these conditions mean that appropriate specialist referral—to gynaecology for endometriosis or hepatology/gastroenterology for liver disease—ensures accurate diagnosis and management. (NICE NG73; NICE NG49; NICE DG34; BSG Guidelines on abnormal liver blood tests and NAFLD risk stratification)

When to Seek Medical Advice for Abdominal Symptoms

Recognising when abdominal symptoms warrant medical evaluation is essential for timely diagnosis and management of both endometriosis and fatty liver disease. Patients should be aware of specific warning signs and symptom patterns that require professional assessment.

Seek prompt GP consultation if you experience:

• Persistent or worsening pelvic or abdominal pain that interferes with daily activities, particularly if cyclical or associated with menstruation

• Heavy, painful, or irregular periods accompanied by pelvic pain or pain during intercourse

• Difficulty conceiving after 12 months of regular unprotected intercourse (or 6 months if aged over 35)

• Unexplained fatigue accompanied by abdominal discomfort, particularly if you have metabolic risk factors

• Right upper quadrant pain that is persistent or recurrent, especially if associated with nausea or jaundice

Urgent medical attention (same-day GP appointment or NHS 111) is warranted for:

• Severe, sudden-onset abdominal pain that differs from previous symptoms

• Pain accompanied by fever, vomiting, or inability to eat or drink

• Yellowing of skin or eyes (jaundice), dark urine, or pale stools

• Abdominal swelling or distension that develops rapidly

Emergency assessment (999 or A&E) is required for:

• Severe abdominal pain with collapse, fainting, or shock

• Abdominal pain with vaginal bleeding in pregnancy (potential ectopic pregnancy; women with endometriosis have a slightly increased risk, but seek emergency care regardless of risk factors)

When consulting your GP, provide comprehensive information including pain location, timing, relationship to menstrual cycle, associated symptoms, family history, and any metabolic risk factors (diabetes, obesity, high cholesterol). This enables appropriate initial investigations and specialist referral when indicated.

NICE guidance recommends that women with suspected endometriosis should be referred to gynaecology. For suspected NAFLD, risk stratification using non-invasive fibrosis tests (such as the ELF test, recommended by NICE, or FIB-4/NAFLD fibrosis score and transient elastography, widely used in UK pathways) guides referral to hepatology services when advanced fibrosis is suspected. Early diagnosis improves outcomes for both conditions, with endometriosis management potentially preserving fertility and fatty liver disease intervention reducing progression to cirrhosis. Do not dismiss persistent symptoms as "normal"—advocate for thorough investigation if your concerns are not adequately addressed. (NICE NG73; NICE NG49; NICE DG34; NHS Endometriosis page; NHS Ectopic pregnancy page)

Frequently Asked Questions